Eyenovia, INC 8-K filings

Hyperion DeFi announced record Q2 2026 net income of $31.0M and adjusted EBITDA of $53.7M, driven by strong operating momentum and new strategic agreements.

Hyperion DeFi, Inc. announced new employment agreements for its CEO, CFO, and General Counsel, effective July 7, 2026, standardizing terms and enhancing severance packages.

Hyperion DeFi, Inc. held its 2026 Annual Meeting of Stockholders on June 30, 2026, where directors were elected and the appointment of its independent auditor was ratified, though a proposal to allow action by written consent failed.

Hyperion DeFi is terminating its agreements with Native Markets and Felix Foundation to reposition 800,000 HYPE tokens.

Hyperion DeFi announced record net income and adjusted EBITDA for Q1 2026, driven by strong performance in its DeFi operating segments, and has raised its full-year 2026 guidance.

Hyperion DeFi, Inc. announced the pricing of its public offering of 2,777,778 shares of common stock at $3.60 per share, expecting to raise approximately $10.0 million in gross proceeds.

Hyperion DeFi reports strong Q4 2025 growth in its DeFi operating businesses, exceeding guidance, alongside a significant net loss and a strategic move to monetize its Life Sciences segment.

Hyperion DeFi, Inc. announced the appointment of Hyunsu Jung as permanent CEO and Robert Rubenstein as General Counsel, alongside a conversion of Series A Preferred Stock into common shares.

Hyperion DeFi, Inc. has updated its risk factors, detailing significant volatility, regulatory uncertainty, and operational challenges associated with its HYPE token treasury strategy.

Hyperion DeFi, Inc. has entered into a sales agreement to offer and sell up to $500 million of its common stock through an at-the-market offering.

Hyperion DeFi, Inc. announced record net income of $6.6 million for Q3 2025, driven by its new digital asset treasury strategy and significant growth in HYPE token staking.

Hyperion DeFi announced two strategic agreements, including a joint validator operation and a perpetual futures market launch, while also confirming its CEO's departure.

Hyperion DeFi, Inc. announced the resignation of Michael Rowe from its Board of Directors, effective September 30, 2025.

Hyperion DeFi, Inc. announced the appointment of David Knox, a former PayPal and SoFi executive, as its new Chief Financial Officer, Treasurer, and Secretary, effective September 29, 2025.

Hyperion DeFi, Inc. increased its at-the-market equity offering program with Chardan Capital Markets, LLC from $50 million to $100 million, having already sold $29.0 million.

Hyperion DeFi, Inc. announced it has regained compliance with Nasdaq's minimum equity requirement and made significant changes to its executive leadership and board.

Hyperion DeFi, Inc. increased its authorized common and preferred stock and reported the results of its 2025 Annual Meeting of Stockholders, where all proposals passed except for enabling stockholder action by written consent.

Hyperion DeFi, formerly Eyenovia, announced a strategic shift to decentralized finance, a $50 million private placement, and a reduced net loss for Q2 2025.

Eyenovia, Inc. has officially rebranded as Hyperion DeFi, Inc., shifting its core strategy to a cryptocurrency treasury reserve focused on the HYPE token, alongside a new Nasdaq ticker symbol HYPD and the departure of its Chief Operating Officer.

Eyenovia, Inc. announces a significant strategic shift to incorporate a Hyperliquid HYPE token treasury and co-branded validator, alongside its ongoing ophthalmic technology development, aiming to provide shareholders with exposure to the rapidly growing Hyperliquid ecosystem.

Eyenovia, Inc. has announced a $50 million private placement to fund a new cryptocurrency treasury strategy focused on Hyperliquid's HYPE token, alongside significant debt restructuring and key management changes.

Eyenovia, Inc. has entered into a Third Amendment to its Loan and Security Agreement, adjusting the terms for lenders to convert up to $10.0 million of outstanding principal into common stock, including beneficial ownership limitations and provisions for fundamental transactions.

Eyenovia reports progress on a potential merger with Betaliq, development of the Optejet UFD, and first quarter 2025 financial results, highlighting a significant reduction in cash burn.

Eyenovia, Inc. has replaced Marcum LLP with CBIZ CPAs as their independent auditor for the year ending December 31, 2025, following CBIZ's acquisition of Marcum's attest business.

Eyenovia, Inc. received a notice from Nasdaq stating that its stockholders' equity is below the minimum requirement for continued listing, prompting the company to submit a plan to regain compliance.

Eyenovia and Betaliq have entered into a non-binding letter of intent for a reverse merger, seeking to combine their technologies and create a new publicly-listed eye care company.

Eyenovia, Inc. has been notified by Nasdaq that it has regained compliance with the minimum bid price requirement, allowing its common stock to continue listing on the Nasdaq Capital Market.

Eyenovia amends its loan agreement with Avenue Capital, deferring principal and interest payments until September 2025 and granting lenders the option to convert up to $10 million of debt into equity.

Eyenovia, Inc. has enacted a 1-for-80 reverse stock split to meet the minimum bid price requirement for continued listing on the Nasdaq Capital Market.

Eyenovia, Inc. will implement a 1-for-80 reverse stock split to meet Nasdaq's minimum bid price requirement, effective January 31, 2025.